Share：
Share this content in WeChat
X
[Chinese][PDF]70380
• Glioma Papers •
Status of radiomics in cerebral giomas
CHEN Xu-zhu  MA Jun 

DOI:10.12015/issn.1674-8034.2018.10.001.


[Abstract] Radiomics can analyze, refine, and quantify medical imaging data, which is helpful for further understanding of molecular (genetic) pathology and clinical biology of tumors. This is instructive for the treatment and prognosis of the patients. This paper is to review the application and further progression of radiomics in cerebral glioma.
[Keywords] Radiomics；Glioma；Magnetic resonance imaging

CHEN Xu-zhu Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

MA Jun* Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

*Correspondence to: Ma J, E-mail: dr_ma@sina.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work was part of National Natural Science Foundation of China No. 81772005, 61771325 High Level Health Technical Personnel Training Funding of Beijing Municipal Health Department of China No. 2015-3-042
Received  2018-04-22
Accepted  2018-07-26
DOI: 10.12015/issn.1674-8034.2018.10.001
DOI:10.12015/issn.1674-8034.2018.10.001.

[1]
Incoronato M, Aiello M, Infante T, et al. Radiogenomic analysis of oncological data: a technical survey. Int J Mol Sci, 2017, 18(4): E805.
[2]
Nandu H, Wen PY, Huang RY. Imaging in neuro-oncology. Ther Adv Neurol Disord, 2018, 11: 1-19.
[3]
Hyare H, Thust S, Rees J. Advanced MRI techniques in the monitoring of treatment of gliomas. Curr Treat Options Neurol, 2017, 19(3): 11.
[4]
Lopez CJ, Nagornaya N, Parra NA, et al. Association of radiomics and metabolic tumor volumes in radiation treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 2017, 97(3): 586-595.
[5]
Larue RT, Defraene G, De Ruysscher D, et al. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol, 2017, 90(1070): 20160665.
[6]
Kickingereder P, Götz M, Muschelli J, et al. Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin Cancer Res, 2016, 22(23): 5765-5771.
[7]
Grossmann P, Narayan V, Chang K, et al. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol, 2017, 19(12): 1688-1697.
[8]
Davnall F, Yip CS, Ljungqvist G, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. Insights Imaging, 2012, 3(6): 573-589.
[9]
Zhou M, Scott J, Chaudhury B, et al. Radiomics in brain tumor:image assessment, quantitative feature descriptors, and machine-learning approaches. AJNR Am J Neuroradiol, 2018, 39(2): 208-216.
[10]
Wu G, Chen Y, Wang Y, et al. Sparse representation-based radiomics for the diagnosis of brain tumors. IEEE Trans Med Imaging, 2018, 37(4): 893-905.
[11]
Li ZC, Bai H, Sun Q, et al. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: a multicentre study. Eur Radiol, 2018, 28(9): 3640-3650.
[12]
Rathore S, Akbari H, Doshi J, et al. Radiomic signature of infiltration in peritumoral edema predicts subsequent recurrence in glioblastoma: implications for personalized radiotherapy planning. J Med Imaging (Bellingham), 2018, 5(2): 21219.
[13]
Li Q, Bai H, Chen Y, et al. A fully-automatic multiparametric radiomics model: towards reproducible and prognostic imaging signature for prediction of overall survival in glioblastoma multiforme. Sci Rep, 2017, 7(1): 14331.
[14]
Kickingereder P, Neuberger U, Bonekamp D, et al. Radiomic subtyping improves disease stratification beyond key molecular, clinical and standard imaging characteristics in patients with glioblastoma. Neuro Oncol, 2018, 20(6): 848-857.
[15]
Papp L, Pöetsch N, Grahovac M, et al. Glioma survival prediction with the combined analysis of in vivo 11C-MET-PET, ex vivo and patient features by supervised machine learning. J Nucl Med, 2018, 59(6): 892-899.
[16]
Lopez CJ, Nagornaya N, Parra NA, et al. Association of radiomics and metabolic tumor volumes in radiation treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 2017, 97(3): 586-595.
[17]
Kickingereder P, Götz M, Muschelli J, et al. Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-Angiogenic treatment response. Clin Cancer Res, 2016, 22(23): 5765-5771.
[18]
Kang D, Park JE, Kim YH, et al. Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation. Neuro Oncol, 2018 DOI: . DOI: 10.1093/neuonc/noy021.
[19]
Xi YB, Guo F, Xu ZL, et al. Radiomics signature: a potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. J Magn Reson Imaging, 2018, 7(5): 1380-1387.
[20]
Tian Q, Yan LF, Zhang X, et al. Radiomics strategy for glioma grading using texture features from multiparametric MRI. J Magn Reson Imaging, 2018 DOI: . DOI: 10.1002/jmri.26010.
[21]
Zhang X, Tian Q, Wang L, et al. Radiomics strategy for molecular subtype stratification of lower-grade glioma: detecting IDH and TP53 mutations based on multimodal MRI. J Magn Reson Imaging, 2018 DOI: . DOI: 10.1002/jmri.25960.
[22]
Li Y, Liu X, Qian Z, et al. Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature. Eur Radiol, 2018, 28(7): 2960-2968.
[23]
Li Y, Liu X, Xu K, et al. MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis. Eur Radiol, 2018, 28(1): 356-362.
[24]
Yu J, Shi Z, Lian Y, et al. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol, 2017, 27(8): 3509-3522.

PREV Research progresses of multimodal magnetic resonance imaging in uterine leiomyoma
NEXT An update of radiogenomics based on MRI features in glioma
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn